M
MPLT
MapLight Therapeutics, Inc.
11.36
+0.15+1.34%Closed19:30 08/24 EDT
OPEN/PREV CLOSE11.21/11.21
TODAY RANGE10.51-11.44
VOL563.46K
MARKET CAP526.85M
52 WEEK RANGE9.10-40.43
AVG VOL (3M)814.61K
% TURNOVER1.21%
TURNOVER--
P/E (TTM)-0.9060
% RANGE8.30%
EPS(TTM)-12.5386
P/E(FORWARD)-2.2980
P/B1.482
BVPS7.67
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP185.56M
SHARES OUTSTANDING46.38M
NEXT EARNINGS12/01-12/10
FREE FLOAT16.33M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·08/17 12:57
Morgan Stanley Keeps Their Hold Rating on MapLight Therapeutics, Inc. (MPLT)
TipRanks·08/17 07:34
MapLight Therapeutics announces $150M private placement
TipRanks·08/16 13:23
MapLight Therapeutics price target lowered to $31 from $35 at Raymond James
TipRanks·08/16 13:18
MapLight Therapeutics price target lowered to $21 from $24 at Canaccord
TipRanks·08/14 14:40
Analysts’ Top NA Picks: Solv Energy (MWH), MapLight Therapeutics, Inc. (MPLT)
TipRanks·08/13 21:30
MapLight Bolsters Schizophrenia Program With New Financing Round
Seeking Alpha·08/13 20:57
MapLight Therapeutics, Inc. GAAP EPS of -$1.32 misses by $0.01
Dow Jones·08/13 20:05
Press Release: MapLight Therapeutics Reports -2-
Seeking Alpha·08/13 13:49
MapLight Therapeutics secures $150M in PIPE funding
Dow Jones·08/10 20:00
MapLight Therapeutics Price Target Cut to $13.00/Share From $52.00 by UBS
Dow Jones·08/10 20:00
MapLight Therapeutics Cut to Neutral From Buy by UBS
Benzinga·08/10 19:51
UBS Downgrades MapLight Therapeutics to Neutral, Lowers Price Target to $13
Same Industry
Name/Symbol
Change%
Price